title: An evaluation of the relative efficacy of a new formulation of oxytetracycline for the treatment of undifferentiated fever in feedlot calves in western Canada.
abstract: A field trial was performed under commercial feedlot conditions in western Canada to compare the efficacy of a new formulation of long-acting oxytetracycline (LA 30) to a standard long-acting oxytetracycline formulation (LA 20) and florfenicol (FLOR) for the treatment of undifferentiated fever (UF) in calves that received metaphylactic tilmicosin upon arrival at the feed-lot. Seven hundred and ninety-seven recently weaned, auction market derived, crossbred, beef calves suffering from UF were allocated to 1 of 3 experimental groups as follows: LA 30, which received intramuscular long-acting oxytetracycline (300 mg/mL formulation) at the rate of 30 mg/kg body weight (BW) at the time of allocation; LA 20, which received intramuscular long-acting oxytetracycline (200 mg/mL formulation) at the rate of 20 mg/kg BW at the time of allocation; or FLOR, which received intramuscular florfenicol administered at the rate of 20 mg/kg BW at the time of allocation and again 48 hours later. Two hundred and sixty-six animals were allocated to the LA 30 group, 265 animals were allocated to the LA 20 group, and 266 animals were allocated to the FLOR group. The relative efficacy of the LA 30 group, as compared with the LA 20 and FLOR groups, was assessed by comparing relapse, chronicity, wastage, and mortality rates. The overall mortality (RR = 0.50) rate in the LA 30 group was significantly (P < 0.05) lower than in the LA 20 group. However, the overall chronicity (RR = 2.56) and overall wastage (RR = 6.97) rates of the LA 30 group were significantly (P < 0.05) higher than in the LA 20 group. There were no significant (P > or = 0.05) differences in UF relapse rates or cause specific mortality rates between the LA 30 and LA 20 groups. In the economic analysis, there was an advantage of $28.59 CDN per animal in the LA 30 group compared with the LA 20 group. The overall chronicity (RR = 2.25) and overall wastage (RR = 2.80) rates of the LA 30 group were significantly (P < 0.05) higher than the FLOR group. There were no significant (P > or = 0.05) differences in UF relapse rates, overall mortality rates, or cause specific mortality rates between the LA 30 and FLOR groups. In the economic analysis, there was an advantage of $12.90 CDN per animal in the LA 30 group compared with the FLOR group. In summary, the results of this study indicate that it is more cost-effective to use a new formulation of long-acting oxytetracycline (300 mg/mL formulation administered at a rate of 30 mg/kg BW) than a standard long-acting oxytetracycline formulation (200 mg/mL formulation administered at a rate of 20 mg/kg BW) or florfenicol for the treatment of UF in feedlot calves that have previously received metaphylactic tilmicosin upon arrival at the feedlot.
authors.affiliation: Feedlot Health Management Services, Bay 7-87 Elizabeth Street, Postal Bag Service #5, Okotoks, Alberta T0L 1T0.
authors.forename: Oliver C
authors.initials: OC
authors.lastname: Schunicht
authors.forename: Calvin W
authors.initials: CW
authors.lastname: Booker
authors.forename: P Timothy
authors.initials: PT
authors.lastname: Guichon
authors.forename: G Kee
authors.initials: GK
authors.lastname: Jim
authors.forename: Brian K
authors.initials: BK
authors.lastname: Wildman
authors.forename: Bruce W
authors.initials: BW
authors.lastname: Hill
authors.forename: Tracy I
authors.initials: TI
authors.lastname: Ward
authors.forename: Stewart W
authors.initials: SW
authors.lastname: Bauck
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D002170:Canada; D002417:Cattle; D002418:Cattle Diseases / Q000188:drug therapy* / Q000191:economics / Q000401:mortality; D002908:Chronic Disease; D003362:Cost-Benefit Analysis; D005334:Fever / Q000188:drug therapy / Q000191:economics / Q000401:mortality / Q000662:veterinary*; D007273:Injections, Intramuscular / Q000662:veterinary; D010118:Oxytetracycline / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D011897:Random Allocation; D012008:Recurrence; D013839:Thiamphenicol / Q000031:analogs & derivatives* / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome; D015431:Weight Loss / Q000187:drug effects
chemical_list: D000900:Anti-Bacterial Agents; C035534:florfenicol; D013839:Thiamphenicol; D010118:Oxytetracycline